Biotech Regulatory Clearances and Edge AI Pivots Prompt Capital Reallocation Across US EquitiesGlobal Report·1 day ago, 04:15 AMBDRX-4.85%MASK-1.29%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·2 days ago, 04:17 AMGENB+2.09%IBRX-1.55%
monday.com's AI Pivot and Tron's Token Buildup Highlight Small-Cap RealignmentsGlobal Report·2 days ago, 04:14 AMMNDY+6.03%MWC+5.73%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·Jul 24 at 04:13 AMINM-4.09%TXG-0.76%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 22 at 04:05 PMZYBT-11.56%CYH-0.37%
Biodexa seeks shareholder approval to adopt new articles of association for E deferred sharesPUBT·Jul 9 at 03:16 PMBDRX-4.85%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 6 at 07:05 AMUPC+1.77%LUCY+18.93%
Biodexa prices $1 million private placement of pre-funded warrants at $2.85 per ADSPUBT·Jun 30 at 07:38 AMBDRX-4.85%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 30 at 07:05 AMUPC+1.77%DCOY-25.79%
Biodexa Pharmaceuticals shares are trading lower after the company announced the pricing of its $3.5 million offering and concurrent private placement of pre-funded warrants and warrants.benzinga_article·Jun 30 at 07:04 AMBDRX-4.85%
Biodexa to issue Series M, N and O warrants with $2.85 exercise price pending shareholder approvalPUBT·Jun 30 at 07:03 AMBDRX-4.85%
Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into CanadaPUBT·Jun 29 at 07:30 AMBDRX-4.85%
